Zolinza Tallies Mixed Results In Relapsed And Refractory Multiple Myeloma ... The Myeloma Beacon All patients had previously received Velcade, 85 percent thalidomide, 71 percent Revlimid, 4 percent pomalidomide, and 74 percent a stem cell transplant. As in the Phase 3 trial of the Zolinza-Velcade combination, participants in the Phase 2 trial ... |
